Premium
Effect of recombinant human granulocyte‐macrophage colony stimulating factor on progenitor cells in patients with advanced malignancies
Author(s) -
Villeval JeanLuc,
Dührsen Ulrich,
Morstyn George,
Metcalf Donald
Publication year - 1990
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.1990.tb02535.x
Subject(s) - progenitor cell , granulocyte macrophage colony stimulating factor , granulocyte , granulocyte colony stimulating factor , immunology , medicine , progenitor , lymphoma , recombinant dna , cfu gm , colony stimulating factor , stem cell , haematopoiesis , chemotherapy , cancer research , biology , cytokine , microbiology and biotechnology , biochemistry , gene
Summary Haemopoietic progenitor cell levels were determined in the blood and marrow of 37 patients with advanced malignancies undergoing a phase I/II clinical trial of 0.3–30 μ g/kg/d recombinant human granulocyte‐macrophage colony stimulating factor (rGM‐CSF). After injection of rGM‐CSF, the absolute number of circulating progenitor cells fell initially but after 4 d of infusion a dose‐dependent increase was observed in progenitor cells of all lineages with a slight bias favouring granulocyte‐macrophage progenitors. A mean 8.4‐fold increase in GM‐CFC and a 3.3‐fold increase in BFU‐E were observed at a dose level of 20 μ g/kg/d of rGM‐CSF. Patients with malignant lymphoma showed a greater response than other patients at the same dose level and the CFU‐E rise correlated with the haematocrit. This study suggests that GM‐CSF may be of value in elevating circulating progenitor cells for subsequent autografting.